Cytotoxic Drug Articles & Analysis
10 news found
Among the prominent offerings by CD Formulation are Antibody Drug Conjugates (ADCs) service. These sophisticated compounds elegantly bind monoclonal antibodies to cytotoxic agents via linkers, targeting specific antigens while minimizing systematic exposure. This technique combines the selectivity of antibodies with the potency of cytotoxic ...
This efficient and highly modular approach has applications in a wide range of fields, including drug discovery, materials science, and bioconjugation. Alfa Chemistry's expanded range of click chemistry reagents now includes DBCO, BCN, and Tetrazines. ...
Biopharma PEG, a leading name in the pharmaceutical industry, is proud to announce a groundbreaking advancement in the field of Antibody-Drug Conjugate (ADC) development. The company now offers monodispersed Polyethylene Glycols (PEGs) on a scale ranging from grams to kilograms, and even on a ton scale. Notable PEGs include mPEG36-NH2, NH2-PEG24-COOH, OH-PEG9-OH, mPEG8-SPA, and ...
The newly introduced solutions are focused on long-acting controlled-release microspheres and phase-transition microneedle patches, to meet the growing demand for novel biopharmaceuticals and biosimilars, while at the same time, improving efficacy, safety, and convenience in drug delivery. Microsphere and microneedle technologies have been gaining increasing popularity in ...
PST Webcast: https://www.webcaster4.com/Webcast/Page/2937/47232 LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including ...
Among such immune checkpoints, PD-1/PD-L1 has been recognized as an anticancer drug target for many years. To date, a variety of monoclonal antibodies targeting the PD-1/PD-L1 signaling pathway have been developed, resulting in encouraging achievements in cancer therapy. ...
In recent years, there has been a global upsurge in the research and development of antibody-drug conjugates (ADCs). ADCs are novel therapeutic biotechnology drugs that are conjugated with monoclonal antibodies and small-molecule drugs with strong cytotoxicity through biologically active linkers. ...
Poor water solubility is one of the most significant barrier limiting drug development. Indeed, more than 40% of compounds identified through combinatorial screening programs display poor aqueous solubility, which is associated with poor bioavailability, suboptimal dosing, etc. ...
Karan Singh attended the conference and offered attendees an eye-opening view of the innovations that are to come to Maxcom that will cover chemicals that are not covered by GHS now, this includes, pharmaceutical drugs, Antineoplastic Drugs (Cytotoxic) and hazardous drugs, biohazardous materials and radioactive isotopes. ...
ByIncora
Cytotoxic drugs (sometimes known as antineoplastics) Describe a group of medicines that contain chemicals which are toxic to cells, preventing their replication or growth, and so are primarily used to treat cancer. ...